CA3105680A1 - Traitement des symptomes prurigineux de la maladie du foie - Google Patents

Traitement des symptomes prurigineux de la maladie du foie Download PDF

Info

Publication number
CA3105680A1
CA3105680A1 CA3105680A CA3105680A CA3105680A1 CA 3105680 A1 CA3105680 A1 CA 3105680A1 CA 3105680 A CA3105680 A CA 3105680A CA 3105680 A CA3105680 A CA 3105680A CA 3105680 A1 CA3105680 A1 CA 3105680A1
Authority
CA
Canada
Prior art keywords
nalbuphine
pruritus
day
itch
liver disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3105680A
Other languages
English (en)
Inventor
Thomas Sciascia
Amale Hawi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trevi Therapeutics Inc
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of CA3105680A1 publication Critical patent/CA3105680A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des méthodes de traitement de patients atteints de prurit associés à une maladie du foie au moyen de compositions antiprurigineuses; des procédés pour traiter des patients ayant un prurit associé à une cholestase obstructive faisant suite à une obstruction du canal biliaire due à une maladie de tissus non hépatiques; et les compositions anti-prurigineuses utilisées dans de tels procédés.
CA3105680A 2018-07-11 2019-07-10 Traitement des symptomes prurigineux de la maladie du foie Pending CA3105680A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696610P 2018-07-11 2018-07-11
US62/696,610 2018-07-11
PCT/US2019/041177 WO2020014342A1 (fr) 2018-07-11 2019-07-10 Traitement des symptômes prurigineux de la maladie du foie

Publications (1)

Publication Number Publication Date
CA3105680A1 true CA3105680A1 (fr) 2020-01-16

Family

ID=69138866

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3105680A Pending CA3105680A1 (fr) 2018-07-11 2019-07-10 Traitement des symptomes prurigineux de la maladie du foie

Country Status (8)

Country Link
US (1) US20200016150A1 (fr)
EP (1) EP3820472A4 (fr)
JP (1) JP2021532080A (fr)
KR (1) KR20210031922A (fr)
CN (1) CN112672743A (fr)
AU (1) AU2019301134A1 (fr)
CA (1) CA3105680A1 (fr)
WO (1) WO2020014342A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100580UA (en) 2018-07-23 2021-02-25 Trevi Therapeutics Inc Treatment of chronic cough, breathlessness and dyspnea
JP2023510341A (ja) * 2020-01-10 2023-03-13 トレビ セラピューティクス インコーポレイテッド ナルブフィン投与メソッド

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170016983A (ko) * 2014-06-13 2017-02-14 트레비 테라퓨틱스, 인코포레이티드 가려움증을 치료하기 위한 방법
AU2017238051B9 (en) * 2016-03-21 2022-11-03 Trevi Therapeutics, Inc. Treatment of uremic pruritus
CN109640981A (zh) * 2016-06-29 2019-04-16 曼隆治疗公司 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途
JP2019532112A (ja) * 2016-10-25 2019-11-07 トレビ セラピューティクス インコーポレイテッド 結節性痒疹の治療方法

Also Published As

Publication number Publication date
US20200016150A1 (en) 2020-01-16
JP2021532080A (ja) 2021-11-25
EP3820472A1 (fr) 2021-05-19
CN112672743A (zh) 2021-04-16
WO2020014342A1 (fr) 2020-01-16
EP3820472A4 (fr) 2022-04-13
AU2019301134A1 (en) 2021-01-21
KR20210031922A (ko) 2021-03-23

Similar Documents

Publication Publication Date Title
AU2018214098B2 (en) Methods for treating pruritus
US20230338367A1 (en) Treatment of prurigo nodularis
US20190099416A1 (en) Methods for treating pruritus
US8987289B2 (en) Methods for treating pruritus
US20170000782A1 (en) Methods for treating pruritus
US10238646B2 (en) Methods for treating pruritus
US20170216277A1 (en) Therapeutic use of nalbuphine without aquaretic effects
CA3105680A1 (fr) Traitement des symptomes prurigineux de la maladie du foie
EP3432871B1 (fr) Traitement du prurit urémique
US20220265640A1 (en) Methods of administering nalbuphine
WO2024020598A1 (fr) Procédés d'administration de nalbuphine